The MarketWatch News Department was not involved in the creation of this content. -- Gyre Pharmaceuticals completed a Pre-NDA meeting with China's CDE, which agreed that the existing Phase 3 clinical ...
Gyre Therapeutics (GYRE) announced that its majority-owned subsidiary in China, Gyre Pharmaceuticals Co., Ltd., completed a Pre-New Drug Application communication meeting with the Center for Drug ...
SAN DIEGO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (Gyre or the Company) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing ...
Gyre Pharmaceuticals completed a Pre-NDA meeting with China’s CDE, which agreed that the existing Phase 3 clinical data support a conditional approval filing for Hydronidone and priority review ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results